Objectives: To compare toxicity reporting between patients and clinicians in the case of systemic chemotherapy for urothelial carcinoma. Methods: Between June 2013 and March 2016, 100 urothelial carcinoma patients received two courses of chemotherapy of gemcitabine plus cisplatin or gemcitabine plus carboplatin, and they were prospectively enrolled in the present study. During chemotherapy, patients answered European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire C30 quality-of-life questionnaires, including four toxicity-related symptoms (appetite loss, nausea, constipation and diarrhea). Clinicians evaluated adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Differences of toxicity reporting were compared between patients and clinicians. Logistic regression analyses were carried out to investigate potential factors for underreporting by clinicians. Results: Toxicity underreporting was most frequently for diarrhea (44%), followed by appetite loss (39%), constipation (33%) and nausea (22%). In total, toxicity underreporting was observed in 72% of patients. Background-adjusted logistic regression analyses showed pretreatment quality-of-life items of global, symptomatic scores to be predictors for toxicity underreporting by clinicians. The limitations of the present study included its retrospective nature and small sample size. Conclusions: Toxicity underreporting by clinicians is frequent in urothelial carcinoma patients receiving systemic chemotherapy. Pretreatment quality-of-life evaluation is essential not only for quality-of-life evaluation, but also to identify potential individuals at risk for toxicity underreporting.
Introduction
In recent years, reflecting an increasing focus on a patient-centered view, an interest in patient-reported outcomes to treatment-related toxicity evaluation has been growing. 1, 2 Although adverse events in chemotherapy are assessed and reported by clinicians, its accuracy in symptom assessment has been questioned, and it has been reported that symptomatic toxicities associated with anticancer treatments are frequently underreported by clinicians, even when data are prospectively collected within clinical trials. 3, 4 It is wellrecognized that clinician-reported outcomes are neither sensitive nor specific in detecting common chemotherapy-related adverse events, and patient-reported outcomes in the evaluation of toxicity of anticancer treatments essential. 5 However, insufficient evidence comparing patient-reported and clinician-reported outcomes in urothelial cancer is available. 6 In addition, few studies have investigated the GCis or GCb patients with urothelial carcinoma. [7] [8] [9] Therefore, we compared patient reporting of four symptoms (appetite loss, nausea, constipation and diarrhea) using a validated instrument, QLQ-C30, with clinicians' reporting of the same symptoms. The present study was registered as a clinical trial: UMIN000020784.
Methods Ethics statement
This study was carried out in accordance with the ethical standards of the Declaration of Helsinki, and was approved by the ethics review board of the Hirosaki University School of Medicine (the authorization number: 2013-075). All participants provided written informed consent.
Patient selection
Between June 2013 and December 2016, we treated 120 consecutive patients with locally advanced or metastatic urothelial carcinoma who received two courses of chemotherapy (GCis or GCb) at Hirosaki University Hospital, Hirosaki, Japan. Regimens were selected based on guidelines regarding eligibility for proper use of cisplatin. 10 Of 120 patients, informed consent was obtained for 100 patients, who were prospectively enrolled in the present study.
Systemic chemotherapy
All urothelial cancer patients received chemotherapy on hospitalization. Patients received either 800 mg/m 2 gemcitabine on days 1, 8 and 15 plus 70 mg/m 2 GCis on day 2 every 3 weeks, or 800 mg/m 2 gemcitabine on days 1, 8 and 15 plus GCb at an area under the curve of four according to the Calvert formula on day 2 every 3 weeks for two cycles.
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Evaluation of toxicity
We evaluated patient-reported QOL using the QLQ-C30 on days 1 (the first day of chemotherapy), 3 and 15 in each cycle. The questionnaire includes five functioning scales (physical, social, role, cognitive and emotional functioning), nine symptom scales (fatigue, pain, nausea, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and financial difficulties) and a scale for global health status/QOL (global QOL). A higher global QOL scale is related to better QOL status. In contrast, higher functional and symptom QOL scales are related to poor QOL status. Response categories for each item range from 1 to 4, which are: (i) not at all; (ii) a little; (iii) quite a bit; and (iv) very much, with a higher score indicating more severe and/or frequent symptoms. In global QOL, response categories for each item range from 1 to 7, with a lower score indicating poor general QOL status. Clinicians recorded toxicity according to the CTCAE version 4.0. Both QLQ-C30 and CTCAE reports were collected separately, and reconciled at the time of data analysis.
We retrospectively evaluated maximum toxicity reporting for four major gastrointestinal toxicities (appetite loss, nausea, constipation and diarrhea) in all cycles, and compared the difference of toxicity reporting between patients and clinicians. For our analysis, any grade coded by clinicians as >0 (by CTCAE) or by patients as >1 (by QLQ-C30) were deemed "toxicity positive," whatever the grade. We categorized report discrepancy between patients and clinicians in three situations: agreement (QLQ was positive in patients, and clinicians did report that symptom as toxicity, or QLQ was negative in patients, and clinicians did not report that symptom as toxicity), overreported (QLQ was negative, but clinician did report that symptom as a toxicity) and underreported (QLQ was positive, but clinician did not report that symptom as a toxicity). Rates of patients with underreporting were calculated in each symptom. Cohen's kappa (j) values were calculated as a measure of agreement between pairs for each symptom. 13 A kappa value <0.4 suggests poor agreement, 0.4-0.75 implies fair-to-good agreement and ≥0.75 suggests excellent agreement. To evaluate the total value of underreporting, we added the number of underreporting symptoms in each symptom.
Variable evaluations
The variables age, sex, body mass index, ECOG-PS, history of cardiovascular disease, hypertension, type 2 diabetes, regimen of chemotherapy and clinical stage were recorded for all participants. Renal function was assessed according to eGFR using a modified version of the abbreviated Modification of Diet in Renal Disease Study formula for Japanese patients. 14 
Statistical analysis
Statistical analyses of clinical data were carried out using SPSS version 22.0 (SPSS, Chicago, IL, USA) and GraphPad Prism 5.03 (GraphPad Software, San Diego, CA, USA). Categorical variables were compared using the Fisher's exact test or v 2 -test. Quantitative variables were expressed as mean AE standard deviations or median with IQR. Differences between groups were compared using Student's t-test for normally distributed data, or the Mann-Whitney U-test for non-normally distributed data, and differences were considered significant at P < 0.05. To investigate independent factors for underreporting, multivariate analyses were carried out using logistic regression models, and ORs with 95% confidence intervals were calculated. Because of limited sample numbers, we used propensity scores to adjust patient backgrounds. A direct adjustment using propensity score preserved statistical power by reducing covariates into a single variable, as described previously. 15 Propensity scores were calculated using logistic regression analyses of age, sex, ECOG-PS, body mass index and comorbidities (cardiovascular disease or diabetes). The background-adjusted logistic regression model included chemotherapy regimen (GCis or GCb), tumor stage (stage IV or not), pretreatment QLQ-C30 items of global score, functional score, symptom score and propensity score. Table 1 summarizes patients' background. A total of 83 patients received neoadjuvant chemotherapy for localized disease (GCis, n = 39; GCb, n = 44), and 17 received first-line chemotherapy for metastatic disease (GCis, n = 4; GCb, n = 13). Numbers of patients with bladder carcinoma and upper urinary tract carcinoma were 64 and 32, respectively. Because of the patient selections for cisplatin eligibility, median age, male predominance and eGFR levels were significantly greater (76 vs 66 years, P < 0.001), lesser (49% vs 91%, P < 0.001) and lower (46 vs 75 mL/min/1.73 m 2 , P < 0.001) in the GCb group compared with the GCis group, respectively. The major reason for cisplatin ineligibility is impaired renal function (79%), followed by poor PS (17%), heart failure (2%) and hearing loss (2%). Average relative dose intensities did not differ significantly between the GCis (96 AE 8%) and GCb (94 AE 7%) groups (P = 0.589). Tumor locations are shown in Table 1 .
Results
Among four toxicities, toxicity underreporting was most frequently for diarrhea (44%), followed by appetite loss (39%), constipation (33%) and nausea (22%; Fig. 1 ). Agreement ranged between 53% and 66%. Cohen's j value ranged between 0.03 and 0.14. To evaluate the total value of toxicity underreporting, the total number of underreported symptoms from each symptom was presented in Figure 2 . A waterfall plot showed 72% of patients experienced any toxicity underreporting (Fig. 2) . The median underreporting symptom was one (IQR 0-2).
To address whether clinicians pay less attention to the reporting of mild toxicities or not, we compared the severity of toxicity report. To compare symptom grade between different questionnaires, we compared the ratio of patients reported as CTCAE grade 0 from clinicians (no adverse event) to any symptoms from patients (QLQ-C30 score 2, or QLQ-C30 score 3 or 4). Overall, underreporting was observed in all grades. In appetite loss, severe toxicities (score 3) were likely missed significantly (Fig. 3a) . It showed that clinicians reported CTCAE 0 in 29 patients, whereas patient-reported QLQ-C30 score 2 was observed in 50 patients (58%). Although underreporting was not significantly different between the mild (grade 2) and severe symptoms, severe toxicities (score 3 or 4) were missed in all patients (100%) for nausea (Fig. 3b) . Mild toxicities were missed significantly for constipation (Fig. 3c) . For diarrhea, not only mild (92%), but also severe (88%), symptoms were missed frequently (Fig. 3d) .
To evaluate independent factors for underreporting, logistic regression analyses were carried out. To minimize independent factors, propensity scores were used to include patient backgrounds as a single variable for multivariate analysis. Subsequent adjustment using multivariate logistic regression analyses showed that neither chemotherapy regimen nor tumor stage had significant influences on toxicity underreporting, whereas pretreatment QOL status of global (OR 0.33, P = 0.004) and symptomatic (OR 1.72, P = 0.004) scores were selected as potential predictors for toxicity underreporting by clinicians ( Fig. 4 ; Table 2 ).
Discussion
Patient-reported outcomes play important roles in assessments of anticancer treatments. Several previous studies have evaluated QOL during chemotherapy in advanced urothelial carcinoma patients. [16] [17] [18] To our knowledge, this is the first report to compare the difference in toxicity reporting between patients and clinicians during systemic chemotherapy for patients with urothelial carcinoma who underwent GCis or GCb.
The present results suggested, similar to other cancers, substantial rates of patients experienced toxicity underreporting, comparing the report of four symptomatic toxicities of anticancer treatment by patients and clinicians. 5 The median number of underreported symptoms was one, suggested clinicians were not aware at least one toxicity from their patients during chemotherapy. Cohen's kappa values were obviously low (range 0.03-0.14) in the present study. However, it is not surprising considering the many published experiences in other research. [1] [2] [3] [4] 6, 19 Previous reports suggested that nausea was less likely to be missed, whereas appetite loss was frequently underreported. 3 It is noteworthy that severe toxicities were frequently missed for appetite loss (86%), nausea (100%) and diarrhea (88%), when we compared the ratio of patients reported as CTCAE grade 0 from clinicians to any patient-reported symptoms by QLQ-C30 (Fig. 3) . However, those patients have relatively higher pretreatment symptom scores. Therefore, those patients might not make an intensive appeal for symptoms to clinicians. In contrast, clinicians did not assess toxicities using a structured interview in the present study. Toxicity assessments without using a structured interview might be the potential reason for underreporting.
The essential finding of the present study was that pretreatment status has a significant influence on toxicity Logistic regression analysis for independent factors predicting underreporting. Propensity scores were used to include patient backgrounds (age, sex, ECOG-PS, body mass index and comorbidities) as a single variable for multivariate analysis. Subsequent adjustment using multivariate logistic regression analyses shows that neither chemotherapy regimen nor tumor stage had significant influences on toxicity underreporting, whereas pretreatment QOL status of global health status/QOL (OR 0.33, P = 0.004) and symptom scale (OR 1.72, P = 0.004) were selected as potential predictors for toxicity underreporting by clinicians. underreporting. Currently, there is no report for the factor that explains toxicity underreporting by clinicians. In the present study, we initially showed that inferior global QOL or preexisting symptoms were the independent factors that influenced toxicity underreporting. Our results suggested that a favorable pre-existing global QOL scale was negatively correlated with toxicity underreporting (P = 0.028, OR 0.50), and a poor pre-existing symptom QOL scale was positively correlated with toxicity underreporting (P = 0.041, OR 1.33). Because clinicians start toxicity evaluation after chemotherapy initiation, pre-existing symptoms are regarded as nontreatment-related symptoms. In addition, patients might not present those symptoms until they are questioned. Therefore, clinicians might miss those symptoms, and it could result in underreporting. However, it remains unclear whether preexisting symptoms should be subtracted when reporting toxicities. In terms of data analysis, no standardized methods were available in the management of pre-existing symptoms. When focusing only on the treatment-related toxicities, the subtraction approach provides an opportunity to control for preexisting symptoms in toxicity assessment. Although this approach is commonly used in regulatory agencies, it is not common for clinical trials. It is reported that the subtraction approach generally evaluates a lower cumulative incidence of toxicity. 20 In contrast, our non-subtraction approach showed that pre-existing symptoms had an adverse influence on toxicity underreporting. Further studies are necessary to develop optimal methods for the handling of pre-existing symptoms.
There are several potential factors to explain underreporting by clinicians. 4 One of the factors to explain underreporting is the degree of symptom severity. It might be true that clinicians pay less attention to reporting minimum or mild symptoms, or those symptoms that do not require additional treatment and/or schedule modification. To address this clinical question, we compared the ratio of the number of patients with CTCAE grade 0 (no adverse event) with the number of patients with QLQ-C30 symptom score severity (mild: QLQ-C30 score 2, or moderate-to-severe: score 3 or 4). In constipation, moderate-to-severe symptoms was not likely missed (20%) compared with mild symptoms (45%) in the present study. Mild constipation could be significantly missed frequently, because clinicians might pay less attention to reporting minimum or mild symptoms. For appetite loss, moderateto-severe symptoms (86%) were significantly underreported by clinicians compared with mild symptoms (58%). These results suggested that toxicity underreporting could happen not only for mild toxicities, but also moderate-to-severe toxicities.
The other reasons are explained by communication between patients and clinicians. 4 Clinicians might be less likely to report a toxicity that is largely expected for the specific agents, suggesting habituation for toxicity as a potential factor for underreporting. In contrast, clinicians might be less likely to ask about unexpected or unusual side-effects. In daily practice, it is typical for patients and clinicians to report toxicity only when clinicians specifically ask, or when it is spontaneously reported by patients. From these considerations, the prevention of underreporting depends on how often clinicians ask patients about toxicity.
However, it is not easy and feasible in daily practice. Therefore, systematic assessment including QOL questionnaires are a key issue to improving the perception gap, administrative efficacy and to prevent the delay in the initiation of treatment for unexpected toxicities. Sharing toxicity information between patients and clinicians provides opportunities to improve risk-benefit evaluation not only in clinical trials, but also daily practice, and provides accurate information for patients based on previous knowledge to their peers.
Limitations of the present study included the small sample size and the single-institution; selection bias according to age, sex, tumor location, limited number of symptoms evaluated and other unmeasurable confounding factors could not be controlled. In addition, toxicity assessment without using a structured interview prevented definitive conclusions in the present study. Because it is difficult to compare symptom grade between different questionnaires, we could not address the feasibility of grade comparison between CTCAE and QLQ-C30 in toxicity underreporting. Therefore, welldesigned, large-scale studies are necessary to validate PROs in urothelial cancer patients. Despite these limitations, we are the first to report difference between patient and clinicians reported outcomes in urothelial carcinoma. Our observation enhances the importance of PROs in clinical trials for urothelial carcinoma.
In conclusion, the present observational study showed that 72 (72%) patients with urothelial cancer experienced toxicity underreporting by clinicians. Pretreatment QOL evaluation is essential not only for QOL evaluation, but also to identify potential individuals who are at risk for toxicity underreporting.
Editorial Comment
Editorial Comment to Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma Modern medicine has been focusing on objective data, such as laboratory results, diagnostic imaging and survival rates, to evaluate the effectiveness of treatments. This methodology is used worldwide, mainly because it eliminates subjective variances due to its high reproducibility, and is a result of a modern shift to evidence-based medicine.
In contrast, if we consider the patients as the ultimate judge of a treatment, the aforementioned objective measurements are not enough to encompass the complete effects of a given treatment. For example, there are cases where laboratory results or image findings show positive improvements, yet patients could not feel any improvements in their symptoms. It is from this aspect that patient-reported outcome must be included in the evaluation process along with conventional indices in order to assess the entire impact of treatments. Also, patient-reported outcomes might hold more weight in urothelial cancer treatment evaluations compared with that of benign diseases that require long-term care, such as diabetes and cardiovascular diseases, because the survival periods of urothelial cancer patients are often limited.
Fukushi et al. should be commended for their attempts to uncover the reasons why symptomatic toxicities during systemic chemotherapy are underreported by clinicians. 1 To my knowledge, this is the first report of such theme in the field of urothelial carcinoma, and the authors hint at the importance of patient-reported outcomes in the treatment process.
Yet, there are concerns about the study's quality of evidence due to the fact that reported outcomes of the same treatments vary from person to person. Different patients might have different opinions about the same treatments because certain factors, such as culture, economic status and generation, affect how a patient feels about a treatment and how it affects their lives. This makes it difficult for researchers to use this methodology on a global scale, as this patient feedback cannot be compared on the same level. Nevertheless, research such as this, which limits the patients to a certain locale and facility, helps create the evidence pool necessary to judge the significance of patient-reported outcomes in treatment evaluation. 
